Angina Pectoris and Myocardial Ischemia in the Absence of Obstructive Coronary Artery Disease: Practical Considerations for Diagnostic Tests
Angina and myocardial ischemia without obstructive coronary artery disease are common clinical findings, often neglected for the assumption of a good prognosis. Most often, such patients are neither further investigated nor offered specific treatment beyond reassurance. However, the absence of significant coronary stenoses on angiography does not necessarily imply a "healthy" coronary tree. In such cases, myocardial ischemia may result from different types of functional disease involving the epicardial coronary arteries, the coronary microcirculation, or both; an accurate assessment of these components should be systematically performed after exclusion of organic epicardial disease because a correct diagnosis has relevant prognostic and therapeutic implications. Here we discuss the basic principles of diagnostic tests in this setting and propose a diagnostic sequence of reasonable practical implementation that may help identify patients at risk of future cardiac events. Myocardial ischemia always results from an imbalance between myocardial metabolic demand and coronary blood supply. In a stable clinical situation, this is mainly related to epicardial atherosclerotic coronary artery disease (CAD), which hinders the dynamic adjustment of coronary blood flow (CBF) to increased myocardial metabolic demand (1) . However, the angiographic evidence of a "normal" or mildly diseased epicardial coronary tree, usually defined as the absence of a luminal diameter reduction of !50% (or >70% of the luminal area reduction) (2) , is a common finding, as it is documented in w20% to 30% of patients undergoing coronary angiography (3) (4) (5) , with a higher prevalence (almost 50%) in women (5) . This condition is usually defined as angina with "normal" coronary arteries, or, more correctly, angina in the absence of obstructive CAD. Here myocardial ischemia may result from different types of functional disease involving the epicardial coronary arteries, the coronary microcirculation, or both (6) . At centers investigating coronary vasomotion after diagnostic angiography, abnormal epicardial and/or microvascular coronary dysfunction can be detected in a large portion (up to 60%) of patients with no or minimal CAD (6) . The large variability of this finding depends on the selection criteria for coronary angiography, the on-site availability of a program to investigate coronary vasomotion, and the procedural protocols specifically elected and adopted.
Patients with stable angina in the absence of obstructive CAD are often inappropriately reassured and even discharged without further investigation or treatment. However, they have an increased mortality, a higher rehospitalization rate, and a worse quality of life compared with healthy subjects (5, 7) . Therefore, there is a true need for a precise diagnostic algorithm that may help identify and treat such patients who appear to be at risk of future cardiac events.
Why Pursue a Correct Diagnosis?
Angina in the absence of obstructive CAD has been associated with a 1.5-fold higher mortality rate compared with a reference population without any evidence of myocardial ischemia (5) . In addition, quality of life is significantly affected because >40% of these patients are rehospitalized for chest pain, and 30% undergo repeat coronary angiography (8) . This obviously means high healthcare costs, similar to those of obstructive CAD.
The prognosis of angina without obstructive CAD is indeed dependent on the underlying pathophysiological mechanisms. Apart from the rare occurrence of organic causes of myocardial ischemia in the absence of significant CAD (Table 1) , ischemic heart disease (IHD) in such cases may result from: 1) a functional disorder (spasm) of the epicardial coronary arteries (paradigmatically with transient ST-segment elevation, so-called Prinzmetal angina, but often with ST-segment depression and/or T-wave changes), whereby an atypical form, termed Prinzmetal X, has been reported as occurring during physical exercise, thus presenting as effort angina (9); or 2) a microcirculatory abnormality in the absence of structural or functional epicardial CAD (the concept of cardiac syndrome X was historically introduced). In such cases, an isolated involvement of the coronary microcirculation can be postulated: both structural and functional abnormalities have been described, with either endothelial dysfunction and reduced bioavailability of the vasodilator nitric oxide or microcirculatory impairment of endothelium-independent vasodilation (10). This condition, today referred to microvascular angina (10), may be idiopathic or secondary to systemic or myocardial diseases. The term cardiac syndrome X should now be abandoned. In the few cases in which the pathogenesis of the syndrome remains unknown and microvascular impairment is not identified, neurological mechanisms also involving changes in pain perception can be hypothesized (11) , and the diagnosis of "true" cardiac syndrome X may still be considered reasonable. Thus, the 3 terms, angina without obstructive CAD, microvascular angina, and "true" syndrome X (Table 2) , should not be used interchangeably, because such conditions have a different prognostic relevance and they require an individualized therapeutic strategy. In Table 2 , we provide a list of definitions, proposed but not universally accepted, to clarify terms and highlight the differences among the various pathological entities.
Microvascular angina accounts for at least one-third of the cases of angina in the absence of obstructive CAD (6); both endothelium-dependent (12) and endothelium-independent (7,13) coronary microvascular dysfunction are predictive of a worse outcome. Patients with coronary endothelial dysfunction showed a 20% higher rate of cardiovascular events (death, acute coronary syndromes, stroke, and need for revascularization) at 46-month follow-up (12) . Among patients with intermediate lesions, microvascular dysfunction was associated with a 3.3-fold increase in the risk of cardiac death at 12 years (36.9%) compared with subjects having a normal endothelial function (7) .
Patients reporting vasospastic angina have a 25% higher probability of experiencing myocardial infarction or cardiac death at 3-year follow-up (14) . A scoring system for predicting adverse cardiac events was recently developed, based on a history of out-of-hospital cardiac arrest (4 points), smoking, angina at rest alone, the presence of organic coronary stenoses, multivessel spasm (2 points each), ST-segment elevation during angina, and the use of b-blockers (1 point each). Patients in the low (<3), intermediate (3 to 5) , and high (>5) score risk strata had a statistically significant (p < 0.001) different incidence of adverse events at 32 months (2.5%, 7.0%, and 13.0%, respectively) (15) .
From a therapeutic standpoint, calcium channel blockers are widely used in patients with vasospastic angina, and their benefits are mainly attributable to their capacity to prevent arterial vasoconstriction by inducing relaxation of vascular smooth muscle cells (16) . Nitrates are also effective in preventing coronary vasospasm (17) . Today b-blockers represent a cornerstone of the pharmacological therapy of IHD, but their role is controversial in patients with vasospastic angina; once believed to be detrimental (18) , thirdgeneration b-blockers were later credited with vasorelaxing properties through adenosine triphosphate efflux-mediated stimulation of nitric oxide from endothelial cells (19) . In patients with microvascular angina, atenolol was proven even more effective than amlodipine and nitrates in suppressing chest pain episodes (20) . Moreover, b-blockers still remain the reference standard for treating patients with a myocardial bridge, mainly due to their negative chronotropic effect. Statins and angiotensin-converting enzyme inhibitors seem to be able to improve exercise capacity in patients with cardiac syndrome X, mainly by improving endothelial function and reducing oxidative stress (21) . However, the evidence of their efficacy is poor and often based on surrogate endpoints and indirect indicators of myocardial ischemia.
In patients with microvascular angina, symptoms often persist despite full classic anti-ischemic therapy. A potential benefit may derive from newer antianginal drugs: compared with placebo, both ranolazine and ivabradine improved symptoms in 46 patients, with ranolazine significantly more effective in increasing the ischemic threshold on the exercise stress test (22) . However, no direct benefit of these drugs on coronary microvascular function was found (22) . In another study carried out in women without obstructive CAD, ranolazine versus placebo improved angina and exerted a favorable effect on myocardial ischemia more evidently in a subgroup of women with altered compared with women with a normal coronary flow reserve (CFR) (23) .
Diagnostic Assessment
Because the pathophysiology of angina without obstructive CAD has relevant prognostic and therapeutic implications, the use of functional testing should be advocated. In this regard, we disagree with the recently issued guidelines of the European Society of Cardiology on stable CAD in which the authors confine adenosine and acetylcholine tests to a weak class of recommendation (IIb) (2). Epicardial vasoreactivity. In patients with angina in the absence of obstructive CAD on angiography, the diagnostic algorithm should first logically exclude organic nonatherosclerotic causes of epicardial CAD (Table 1 ) and significant lesions underestimated by angiography. Intermediate stenoses (50% to 70% diameter reduction), especially when occurring along the same vessel, are worthy of a functional evaluation, now feasible with pressure guidewires through the assessment of the fractional flow reserve (FFR) (24) . An important consideration in this regard is that increased vasoconstrictive tone or the presence of a diffuse and circumferential disease along the vessel may both lead to an underestimation of the reference vessel diameter and therefore of the real extent of a coronary stenosis. In such cases, the intracoronary injection of nitrates fully and selectively dilates normal vessels, thus differentiating between normal and diseased segments (17) . From this assumption, a practical problem arises because pretreatment with intracoronary nitrates may interfere with subsequent vasoreactivity tests. The vasodilatory effect of nitroglycerin peaks at 3 to 5 min 
Tests for Angina Without Obstructive CAD after intracoronary injection and lasts for w12 min in normal segments and 15 min in stenotic segments (25) . Therefore, intracoronary injection of nitrates during diagnostic angiography should be reserved only to those cases in which there is real doubt about the significance of the stenosis. In such cases, a functional evaluation of the coronary artery system should be delayed by at least 15 min.
After excluding significant organic CAD by angiography, functional causes involving the epicardial coronary arteries should be investigated. Vasospasm may occur during daily life in response to various stimuli (smoking, cold, cocaine use, metabolic disturbances, physical or mental stress), and diagnostic protocols combining some of these several stimuli are occasionally adopted. The cold pressor test and/or the hyperventilation test, alone or in combination, are relatively safe vasoconstrictive stimuli and are usually coupled with noninvasive diagnostic tests. Compared with the sole induction/noninduction of angina or ST-segment changes on electrocardiography, echocardiography has better sensitivity and better diagnostic accuracy for coronary vasospasm (60% vs. 91%, respectively) and also permits the identification of the specific myocardial segment(s) undergoing transient ischemia, therefore allowing inferences regarding the culprit coronary artery (26) ( Table 3 ). However, because nonpharmacological spasm-provoking protocols still have an overall poor sensitivity, pharmacological tests are now more widely accepted. Ergonovine (otherwise called ergometrine) is an ergot alkaloid acting as a serotonin agonist that induces vasospasm in patients affected by variant angina via a mechanism mediated by the hypersensitivity of the 1D serotonin receptor subtype in vascular smooth muscle cells. Methylergonovine (methylergometrine) is a synthetic analog of ergonovine, apparently acting not solely on vascular smooth muscle cells but also on the endothelial serotonin receptors, thus inducing a coronary vasospasm that is at least in part caused by endothelial dysfunction (27) . The first provocation tests with ergonovine during coronary angiography were performed in the late 1970s (28) by intravenous injection of either a single bolus of methylergonovine maleate or repeated boluses at increasing doses. The diagnostic detection of vasospasm was at that time obtained either indirectly with noninvasive protocols by electrocardiography (29) or echocardiography (30) or directly by invasive angiography (28) . However, dangerous complications, such as life-threatening arrhythmias, acute myocardial infarction, severe hypotension, and even death were reported after the intravenous administration of ergonovine, which can trigger refractory and multivessel spasms, in some cases without the possibility of a prompt reversal by intracoronary nitrates (31) . Noninvasive ergonovine protocols were thus discouraged, and provocative tests with intracoronary administration were instead advocated (32) ( Table 3 ). The direct intracoronary route appears to be safer and with a similar or even a greater degree of coronary constrictive responses of spasm-prone coronary segments compared with intravenous administration (33) . Thus, intracoronary ergonovine is now recommended by the European guidelines as a valuable alternative to intracoronary acetylcholine to assess epicardial coronary vasospasm (2) .
Acetylcholine produces coronary vasodilation in the presence of a healthy endothelium (34) while causing a paradoxical vasoconstriction when endothelial dysfunction is present (35) (Fig. 1, Table 3 ). The diagnostic accuracy of acetylcholine administration is comparable to that of intracoronary ergonovine (36) . Moreover, acetylcholine has the No demonstration of coronary microcirculation dysfunction (negative acetylcholine and adenosine test results) *Obstructive atherosclerotic CAD is defined in the presence of luminal diameter reduction of !50% (or >70% of luminal area reduction) (2) . yCoronary aneurysms, myocardial bridging, coronary anomalies (as in Table 1 ).
CAD ¼ coronary artery disease.
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advantage of also allowing the identification of a coronary microvascular endothelial dysfunction (as discussed later). At least 2 considerations are, however, still opportune about acetylcholine and ergonovine intracoronary tests: first, their safety still remains a major concern, although it seems to be acceptable because diffuse coronary spasm can be easily reversed by intracoronary nitrate injection. Indeed, excessively aggressive protocols may be responsible for the higher occurrence of major arrhythmias reported with acetylcholine (9.3%) compared with ergonovine (3.2%, p < 0.001) (37) . With slower infusion rates of acetylcholine, only transient atrioventricular blocks, spontaneously resolved in a few seconds due to the short acetylcholine half-life, have been reported (6) . Second, there is no universal consensus on the definition of coronary spasm because visually assessed lumen diameter reductions ranging from 75% to 90% compared with a reference vessel diameter after nitroglycerin injection have been described as spasm (6, 37) . Indeed, the response to vasoconstrictive stimuli can vary. At 1 end of the spectrum is the physiological diffuse and mild vasoconstriction in response to ergonovine observed in normal epicardial coronary arteries; at the other extreme, there is the severe segmental constriction leading to total artery occlusion, as typically observed in patients with variant angina. Intermediate forms of coronary constriction, reducing local diameter by at least 50%, are still of equivocal interpretation, but seem to indicate the potential for the development of occlusive spasm in response to stronger stimulations (38) . The coronary microcirculation: invasive assessment. Once epicardial coronary artery spasm is excluded, involvement of the coronary microcirculation can be hypothesized and should then be actively investigated. The direct assessment of microcirculatory dysfunction is, however, challenging for several reasons. The spatial resolution of coronary angiography is relatively poor (0.5 mm), thus hampering a detailed evaluation of the small resistance vessels (0.1 to 0.3 mm in diameter); techniques required for evaluation of the microcirculation (e.g., acetylcholine and adenosine tests) are considered complex, invasive, time-consuming, or expensive or are still not widely available (e.g., cardiac magnetic resonance imaging).
Coronary microvascular disease may in turn be related to endothelium-dependent or endothelium-independent dysfunction, this latter due to an abnormal response of resistance vessels to direct vasodilatory stimuli. Accordingly, both the endothelium-dependent and the endothelium-independent functions should be assessed.
ASSESSMENT OF ENDOTHELIUM-DEPENDENT CFR. Intracoronary acetylcholine administration during coronary angiography is now considered the reference standard for the evaluation of coronary endothelium-dependent vasodilation (2). After intracoronary injection of acetylcholine, epicardial or microvascular spasms can be detected according to angiographic, electrocardiographic, and clinical findings (6) ( Table 3) .
ASSESSMENT OF ENDOTHELIUM-INDEPENDENT VASODILATION.
In physiological conditions, CBF increases by at least 3 to 4 times in response to increased myocardial oxygen requirements. The ability of CBF to adapt to match the metabolic demand is defined as CFR and is measured as the ratio of the maximal flow after a hyperemic stimulus to the baseline resting blood flow:
, where V indicates the vascular volume between the injection site and the measuring site of the indicator, and Tmn the mean transit time of the indicator to travel from the injection site to the distal sensor (1). Adenosine is an endogenous purine nucleoside physiologically released from ischemic myocardial cells during ischemia. Adenosine causes vascular smooth muscle cell relaxation ( Fig. 1) and is used to cause a massive direct endothelium-independent coronary microvascular vasodilation (Table 3 ). In addition, nicorandil has been proposed as a novel hyperemic agent. Nicorandil is a nicotinamide ester that releases nitric oxide in the same fashion as organic nitrates and opens adenosine triphosphate-sensitive potassium channels, thereby causing dilation of both coronary epicardial arteries and resistance arterioles. In a recent study, the hyperemic efficacy of an intracoronary bolus injection of nicorandil 2 mg was not inferior to the intravenous infusion of adenosine to obtain the FFR and the index of microcirculatory resistance (IMR) (see the following), but also showed a better safety profile (39) ( Table 3) .
CFR can be assessed during coronary angiography by Doppler or thermistor/pressure sensor guidewires. The latter are now preferred because they are more robust than Dopplerderived CFR measurements mainly due to the difficulties of Doppler velocity measurements in differentiating flow velocity signals from vascular wall motion artifacts and for the capacity offered by pressure systems also to measure FFR (40) ( Table 3) . However, CFR assesses the flow of the entire coronary system, and its reductions are sensitive to both epicardial CAD and microcirculatory disease. For this reason, CFR is a valuable index of microcirculatory dysfunction only after excluding the presence of significant epicardial CAD.
IMR ¼ Pd/Tmn À1 , where Pd is the distal coronary pressure, has been proposed to overcome the limits of CFR (41): both Pd and Tmn are obtained after the intracoronary injection of 3 ml of room-temperature saline solution and measured with a pressure wire under full adenosine vasodilation, thus potentially eliminating the variability of resting vascular tone and possible epicardial stenoses. Compared with CFR, IMR provides a more reproducible assessment of the microcirculation, which is independent of hemodynamic perturbations (42) . With a single pressure wire, both FFR Sensor-tipped guidewire (equipped with either a Doppler probe or thermistor/ pressure sensor) advanced through the diagnostic catheter in a stenosis-free area of the epicardial artery. 1. Obtain average baseline CFV 2. Obtain a stable average peak CFV (after 3 adenosine injections over 2 cardiac cycles with a 2-mm sample volume at a location w5 mm distal to the tip of the guidewire). 3. Calculate CFR: ratio of average peak CFV to average baseline CFV.
Positive for coronary microvascular endothelium-independent dysfunction: CFR <2.5 in the absence of significant epicardial coronary artery stenosis (13, 43, 52) Intracoronary nicorandil Intracoronary bolus injection of 2 mg nicorandil
As a hyperemic endotheliumindependent agent, nicorandil allows measurements of: FFR (mean distal coronary pressure divided by mean aortic pressure at maximal hyperemia). IMR (distal coronary pressure at maximal hyperemia multiplied by the hyperemic mean transit time) CFR: ratio of average peak CFV to average baseline CFV.
Positive for coronary microvascular endothelium-independent dysfunction: CFR <2.5 (or an impaired IMR) in the absence of significant epicardial coronary artery stenosis (FFR >0.80).
Transthoracic color Doppler echocardiography
Intravenous administration of adenosine (0.14 mg/kg/min for 90 s).
Transthoracic echocardiography performed in the left lateral decubitus at the cardiac apex to image the distal anteroseptal; then distal left anterior descending artery is visualized by color Doppler and pulsed Doppler is used to measure CFV and CFR (ratio of average peak CFV after adenosine to average baseline CFV).
Positive for coronary microvascular endothelium-independent dysfunction: CFR <2.0 in the absence of significant epicardial coronary artery stenosis (44, 45) Continued on the next page Radico et al.
and IMR can be measured, providing a comprehensive and specific assessment of both epicardial and microvascular coronary physiology. Despite these convincing pathophysiological principles and promising preliminary clinical evidence, data on patients with microvascular angina are scant, and there are no established cut-off values for IMR. Recently, an upper limit of normal set at 29 U, as the highest interquartile range in a population of patients with intermediate coronary artery lesions, was identified (43) . Therefore, its assessment cannot be currently recommended as a reference standard for the assessment of coronary microvascular function. Moreover, an impaired CFR may result not only from increased microvascular resistances, but also from an abnormally increased basal flow velocity, which could be related to altered coronary autoregulation. The latter is proposed as a new pathophysiological mechanism explaining altered CFR in patients with angina without obstructive CAD (7).
The coronary microcirculation: noninvasive assessment.
To overcome the obvious limitations of invasive methods to assess coronary microvascular function, several noninvasive techniques are being developed and validated (Table 3) . Pulsed-wave Doppler recording of CBF in the left anterior descending artery (44) , obtained by transthoracic echocardiography before and after adenosine infusion, is the most reliable noninvasive method to assess CFR (45) and is now suggested by the new European guidelines with the same class of recommendation (IIb) as the intracoronary adenosine test during coronary angiography (2) . Other studies have also proposed using myocardial contrast echocardiography to detect perfusion defects and to estimate CFR (46) .
Perfusion imaging by gadolinium-enhanced stress cardiac magnetic resonance is another promising technique for the identification of subendocardial perfusion defects induced by adenosine through a coronary steal phenomenon in myocardial areas supplied by a dysfunctional microcirculation (47) .
Perfusion imaging with positron emission tomography is also considered an accurate test for the assessment of myocardial blood flow achieved by quantifying the uptake of a specific cardiovascular radioisotopic tracer (48) .
Last, multislice detector computed tomography with an iodinated contrast is capable of providing an estimate of myocardial blood flow and CFR by measuring the attenuation changes over time in basal and hyperemic conditions and plotting time-attenuation curves (49) . Recently introduced 320-row scanners allow the acquisition of a full cardiac tomographic dataset within a single heart beat, reducing iodine contrast volumes and radiation doses (50) .
Unfortunately, these noninvasive methods are all, albeit to a variable degree, expensive and available only in few research centers. Moreover, they still lack sensitivity and 
Myocardial contrast echocardiography
Intravenous administration of an ultrasound contrast agent (microbubbles of sulfur hexafluoride surrounded by a phospholipid shell) and adenosine (0.14 mg/kg/min for 90 s).
Contrast images are acquired in an apical 4-chamber view, and myocardial opacification is quantified in the posterior interventricular septum and lateral left ventricular by a specific software. CFR assessment: comparison of contrast intensity at rest and at peak adenosine.
Positive for coronary microvascular endothelium-independent dysfunction: CFR <2.0 in the absence of significant epicardial coronary artery stenosis.
Adenosine stress perfusion cardiac magnetic resonance
Intravenous administration of gadolinium contrast and adenosine (0.14 mg/kg/ min for 3 min).
Perfusion cardiac magnetic resonance images: adenosine gadolinium firstpass imaging for assessment of stress perfusion repeated after 15 min for assessment of rest perfusion.
Positive for coronary microvascular dysfunction: Reduced or even absent gadolinium enhancement in the corresponding subendocardial layer.
Positron emission tomography perfusion imaging Rb) and adenosine (or dipyridamole).
MBF assessment is achieved by the quantification of the myocardial radioisotopic-tracer uptake. CFR assessment: ratio of MBF in hyperemic conditions and at rest.
Positive for coronary microvascular endothelium-independent dysfunction: CFR <2.5 in the absence of significant epicardial coronary artery stenosis.
Multislice detector computed tomography
Intravenous administration of iodinated contrast and adenosine (0.14 mg/kg/ min for 5 min).
Images are analyzed by measuring the attenuation changes over time in basal and hyperemic conditions and plotting time-attenuation curves. CFR: ratio of area under the curve for the hyperemic territory to the remote territory.
Positive for coronary microvascular endothelium-independent dysfunction: CFR <2.5 in the absence of significant epicardial coronary artery stenosis. Tests for Angina Without Obstructive CAD specificity and are often unable to differentiate between epicardial and microvascular abnormalities. There is also a lack of cross-center validation, which is at the moment a strong source of concern. In conclusion, at present, they only represent promising alternatives to currently available invasive techniques.
Proposal of a Comprehensive Diagnostic Algorithm
Here we propose a diagnostic algorithm (Fig. 2) for patients with typical angina and documentation of myocardial ischemia in the absence of obstructive CAD. In an effort to obtain a good compromise between theoretically ideal tests and practically feasible ones, this scheme should be seen as a work-in-progress and may be refined when better techniques or more complete evaluations of current techniques become available. First of all, every patient undergoing coronary angiography for effort angina and unequivocal signs of exerciseinduced myocardial ischemia should discontinue at least 24 h before the examination any cardiovascular medication able to affect coronary vasomotor responses (6) so as not to preclude a possible functional evaluation of the coronary circulation. Likewise, routine pretreatment with intracoronary nitroglycerin after coronary cannulation should be avoided. It would be also preferable to perform coronary angiography in the morning to take advantage of the low threshold for vasospasm described in the circadian rhythm of vasomotor responses.
When a subcritical or intermediate lesion is documented, FFR should be considered to exclude its functional relevance (nonpathological FFR value !0.80), especially in the presence of a series of moderate lesions in the same vessel, which might produce additive effects (24) . Some concern was recently expressed about the sensitivity of this technique due to a differential reduction of pressure induced by adenosine in coronary and systemic vascular beds (51) and in cases of irreversibly increased microcirculatory resistance (as detected by increased IMR) (43) . Nevertheless, the FFR remains the reference method for assessing lesion functional relevance.
In the absence of significant atherosclerotic lesions or any other nonatherosclerotic epicardial coronary disease (Table 1 ), the acetylcholine test should be performed. When both epicardial coronary spasm and microvascular endothelial dysfunction can be excluded with the acetylcholine test, the presence of an endothelium-independent dysfunction should be investigated with the adenosine test (considered positive when CFR <2.5) (52) .
If, in a patient with typical angina and robust suspicion of myocardial ischemia documented with a noninvasive stress test, neither the acetylcholine test nor the adenosine test reveals any abnormal coronary dysfunction, then a "true" cardiac syndrome Xdpotential myocardial ischemia due to unknown and/or undetectable causesdcan be diagnosed because the probability of a false positive result for the presence of IHD is deemed to be low. Parallel to this group, one should also, however, list subjects with false-negative test results for microvascular angina, such as patients showing a normal FFR, a normal CFR, and an increased IMR, in a condition that Echavarria-Pinto et al. (43) recently classified as "suspected initial microvascular dysfunction." The clinical significance of this condition is currently unknown but worth exploring, provided that such a rigorous definition is applied. The clinical reality may clearly still leave uncertainties of classification, as highlighted in Coronary angiography should be performed in the morning to take advantage of the lower circadian threshold for vasospasm in these hours of the day. Calcium channel blockers, b-blockers, and long-acting nitrates should be discontinued at least 24 h before coronary angiography. A functional evaluation of lesion severity by fractional flow reserve (FFR) (normal values !0.80) is recommended in the presence of a moderate disease, but it might be performed as a confirmation of angiographic findings also in cases of a mild or severe disease. In the absence of a significant organic epicardial disease due to either atherosclerotic (significant atherosclerotic coronary artery disease [CAD]) or to other nonatherosclerotic causes (anomalous coronary origin, myocardial bridge, or coronary aneurysm) (nonatherosclerotic CAD), the acetylcholine test can identify the presence of vasospastic or microvascular angina. When the acetylcholine test result is negative, adenosine testing can explore the presence of a microvascular angina, based on the finding of an impaired coronary flow reserve (CFR) (<2.5). In patients with no CAD and normal acetylcholine and adenosine test results, a potential myocardial ischemia due to unknown and/or undetectable causes can be hypothesized if the probability of a false-negative result for ischemic heart disease (dashed arrow) is thought to be low on the basis of the clinical presentation. Therefore, in such cases, a tentative diagnosis of "true" cardiac syndrome X can here be made; DS ¼ diameter stenosis. 
Conclusions
The failure to detect fixed obstructive CAD in patients with angina and signs of myocardial ischemia is a frequent clinical scenario that can be due to different mechanisms. Because of various prognostic and therapeutic implications, a correct diagnosis of the underlying pathophysiology is warranted and should be actively pursued. The intracoronary acetylcholine test allows at the same time the assessment of a possible epicardial vasospasm and endothelium-dependent microvascular dysfunction. Similarly, the use of a pressure wire with the adenosine test may evaluate both the functional significance of a coronary lesion and endotheliumindependent microvascular dysfunction. A functional assessment of both the epicardial coronary arteries and the coronary microcirculation is strongly recommended to identify patients at higher risk of coronary events and to guide therapeutic strategies and should be much more widely implemented.
